[{"id":"8d195ac4-ff45-457f-b006-0abe5f018000","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006403","created_at":"2023-08-23T15:10:48.638Z","updated_at":"2024-07-02T16:35:38.691Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT06006403","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA positive","tags":["IL6 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD123 targeted CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-30"}]